Clinical Trials Logo

Primary Sjögren's Syndrome clinical trials

View clinical trials related to Primary Sjögren's Syndrome.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04684654 Terminated - Clinical trials for Healthy Participants

BMS-986325 in Healthy Participants and Participants With Primary Sjögren's Syndrome

Start date: February 16, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety, tolerability, drug levels, and drug effects of BMS-986325 in healthy participants and participants with primary Sjögren's syndrome. The results will guide the future clinical development with BMS-986325.

NCT ID: NCT02610543 Terminated - Clinical trials for Primary Sjögren's Syndrome

UCB Proof of Concept Study in Patients With Primary Sjögren's Syndrome

Start date: October 2015
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, double-blind, placebo-controlled, 12-week proof-of-concept study to assess the efficacy, safety, and tolerability of UCB5857 in subjects with primary Sjögren's Syndrome (pSS). The primary objective of this study is to evaluate the efficacy on overall disease activity and safety of UCB5857 added to current treatment relative to placebo in subjects with pSS.

NCT ID: NCT01552681 Terminated - Clinical trials for Primary Sjögren's Syndrome

Baminercept, a Lymphotoxin-Beta Receptor Fusion Protein, for Treatment of Sjögren's Syndrome

Start date: July 2012
Phase: Phase 2
Study type: Interventional

The purpose of the study is to find out if the experimental study agent, baminercept, is effective in treating patients with Sjögren's syndrome. The study will also determine if the study agent can be safely given to patients with Sjögren's syndrome; examine how it affects symptoms of the disease; and attempt to understand how baminercept affects the underlying mechanisms of Sjögren's syndrome and the immune system.